(NASDAQ: AUPH) Aurinia Pharmaceuticals's forecast annual revenue growth rate of 10.47% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Aurinia Pharmaceuticals's revenue in 2025 is $260,111,000.On average, 3 Wall Street analysts forecast AUPH's revenue for 2025 to be $35,739,527,812, with the lowest AUPH revenue forecast at $35,322,788,669, and the highest AUPH revenue forecast at $36,356,080,605. On average, 3 Wall Street analysts forecast AUPH's revenue for 2026 to be $39,673,145,164, with the lowest AUPH revenue forecast at $37,448,605,837, and the highest AUPH revenue forecast at $41,318,514,489.
In 2027, AUPH is forecast to generate $46,669,255,534 in revenue, with the lowest revenue forecast at $45,951,874,509 and the highest revenue forecast at $47,965,806,562.